Brokerages are taking a selective approach in markets: Motilal Oswal has maintained a buy view on UTI AMC, citing steady AUM growth and healthy SIP inflows, as well as a bullish stance on Aditya Birla Sun Life AMC. In contrast, Goldman Sachs downgraded Dr Reddy’s Laboratories, pointing to weak pipeline visibility, pricing pressure, and limited near-term growth.
Swipe through stories, personalise your feed, and save articles for later — all on the app.
